REESE DAVID M 4

What Happened

• David M. Reese, EVP & Chief Technology Officer of Amgen (AMGN), was granted equity on 2026-05-05 and had a small tax-withholding disposition on 2026-05-06.
  • Grant: 2,912 restricted stock units (RSUs) reported as acquired at $0.00.
  • Derivative grant: 19,002 non-qualified stock options (reported as a derivative acquisition) with a strike/ reporting price of $329.59, reported value $6,262,869.
  • Tax withholding: 454 shares were disposed on 2026-05-06 at $329.59 to cover tax liability, yielding $149,634.
• Filing was submitted on 2026-05-07 (covering the 5/5/2026 transactions).

Key Details

• Transaction dates and prices:
  • 5/5/2026: RSU grant — 2,912 shares @ $0.00.
  • 5/5/2026: Option grant (derivative) — 19,002 shares @ $329.59 (value $6,262,869).
  • 5/6/2026: Tax withholding — 454 shares disposed @ $329.59 for $149,634.
• Shares owned after transaction: Not specified in the Form 4 excerpts provided.
• Relevant footnotes:
  • F1: RSUs vest in four equal annual installments (25%/year) beginning 5/5/2027, prorated for months worked in 2026; vested RSUs paid 1:1 in common shares.
  • F2: 415 Dividend Equivalents are included in the RSUs and will be paid in shares according to the vesting schedule.
  • F3: The 19,002 instruments are non‑qualified stock options that vest in four equal annual installments starting 5/5/2027, prorated for 2026 service.
• Filing timeliness: Form filed 5/7/2026 for transactions on 5/5–5/6/2026 — appears timely.

Context

• The 19,002‑share entry is an option grant (a derivative award), not an immediate purchase of common stock; vesting begins 5/5/2027.
• The 454‑share disposition is a tax‑withholding event (common when RSUs are issued or vest), not an open‑market sale expressing sentiment.
• These are routine compensation awards to an executive; they do not alone indicate buy/sell sentiment.